Medivir AB (Medivir AB) ROCE % : -48.20% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Medivir AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medivir AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -48.20%.

Medivir AB ROCE % Historical Data

The historical data trend for Medivir AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB ROCE % Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-42.43

-22.85

-26.53

-32.41

-40.84

Medivir AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-39.49	-61.07	-63.68	-39.85	-48.20

Medivir AB ROCE % Calculation

Medivir AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.619	/	( ( (22.567 - 2.699)	+	(28.068 - 5.725) )	/ 2 )
	=	-8.619	/	( (19.868	+	22.343)	/ 2 )
	=	-8.619	/	21.1055
	=	-40.84 %

Medivir AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-10.528	/	( ( (28.068 - 5.725)	+	(25.588 - 4.245) )	/ 2 )
	=	-10.528	/	( ( 22.343	+	21.343 )	/ 2 )
	=	-10.528	/	21.843
	=	-48.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Medivir AB (OTCPK:MVRBY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medivir AB ROCE % Related Terms

Thank you for viewing the detailed overview of Medivir AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.